Connect
← Return to Trying to decide on treanment
Discussion
Prostate Cancer | Last Active: 41 minutes ago | Replies (11)
Comment receiving replies
Depends on how much you favor proton and if you want 1-2 vs 5-6 weeks of treatment. I assume the proton is SBRT high dose type to give you the equivalent biological dose as the IMRT and the HDR and ADT protocols are about the same for both choices. The studies that have been done seem to show about the same long term (about 5 years) results for SBRT as IMRT at the same biological dose levels. That said I did not think there was enough difference to cash pay for Proton vs. having adaptive IMRT paid by my commercial insurance.
Replies to "Depends on how much you favor proton and if you want 1-2 vs 5-6 weeks of..."
Connect
@jim18 Hi thanks for the reply. Yes the trial is hypofractionated whole pelvis proton therapy. If your insurance would cover Proton would you go that route?
This is from trial consent form:
Search > Prostate Cancer
Apply to Trial
Compensation: Varies
Number of Visits: 5
Duration: 5 weeks (one Proton session per week)
Apply Today
30 Participants Needed
Share
Trial Listing ImageAbramson Cancer Center at Penn Medicine logo
Proton Therapy and Brachytherapy for Prostate Cancer
Recruiting in Philadelphia (< 50 mi)
PM
Overseen By
Project Manager
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Abramson Cancer Center at Penn Medicine
Must be taking: Androgen deprivation
Must not be taking: Therapeutic anticoagulation
Disqualifiers: Metastatic disease, Prior radiation, others
No Placebo Group
All trial participants will receive the active study treatment (no placebo)
Prior Safety Data
This treatment has passed at least one previous human trial
Approved in 2 Jurisdictions
This treatment is already approved in other countries
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to treat prostate cancer that is high risk or may spread to nearby lymph nodes. Researchers aim to determine if combining two radiation treatments, delivered in fewer sessions with a higher dose each time, is safe and effective. This method, called Hypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost, combines proton therapy and brachytherapy. The trial seeks participants diagnosed with high or intermediate-risk prostate cancer, who have not received prior radiation in the pelvic area, and do not have certain health conditions like inflammatory bowel disease. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in prostate cancer treatment.
What evidence suggests that hypofractionated whole pelvis proton therapy with brachytherapy boost might be an effective treatment for prostate cancer?
This trial will evaluate the safety and effectiveness of using proton therapy with a brachytherapy boost for treating high-risk prostate cancer. Research has shown that a shorter, more intense form of radiotherapy, combined with a brachytherapy boost, can be safe and effective. Studies have found that this approach has manageable side effects related to urinary and bowel functions, common concerns in prostate cancer treatments. Additionally, ongoing research compares this method to other treatments, highlighting its potential benefits. This suggests that the treatment could effectively target prostate cancer while minimally impacting patients' quality of life.